Tracey Vlahovic, DPM
Foot & Ankle Surgery · San Francisco, CANPI 1528053535
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $239,607 of the $313,120 with a category attached, or 76.5%. Ortho Dermatologics, A Division Of Bausch Health US, LLC accounts for 99.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $117,302 and has fallen 87.5% since, to $14,679 in 2025. Among foot & ankle surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $679.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$311K
- Alafair Biosciences, Inc.$345
- Stryker$310
- Musculoskeletal Transplant Foundation Inc.$258
- Amgen$157
- Geistlich Pharma, North America, Inc.$132
- plus $780 from 17 others
What the payments were for
- Consulting fees$29,90710%
- Speaking & faculty fees$239,60777%
- Travel & lodging$32,90811%
- Food & beverage$10,2873%
- Education$4130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 424 | $311,138 |
| Alafair Biosciences, Inc. | 2 | $345 |
| Stryker(2 entities) | 4 | $310 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $258 |
| Amgen | 3 | $157 |
| Geistlich Pharma, North America, Inc. | 1 | $132 |
| Organogenesis Inc. | 2 | $126 |
| Johnson & Johnson | 1 | $125 |
| Kerecis Limited | 2 | $74 |
| Sebela Pharmaceuticals Inc. | 3 | $69 |
| Bristol Myers Squibb | 3 | $69 |
| Paratek Pharmaceuticals, Inc. | 2 | $48 |
| Almirall LLC | 1 | $39 |
| Nevro Corp. | 2 | $37 |
| Medtronic | 1 | $35 |
| Dermavant Sciences, Inc. | 1 | $29 |
| Sandoz | 2 | $29 |
| Smith+Nephew | 1 | $24 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Mimedx Group, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Convatec Inc. | 1 | $13 |
| Biotissue Holdings Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$313,120 in reported general payments places this provider in the 95th percentile of 1,126 foot & ankle surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Calcipotriene | 12 | $1,885 |
| Ciclopirox | 70 | $1,616 |
| Betamethasone Dipropionate | 11 | $631 |
| Ammonium Lactate | 14 | $305 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in San Francisco
- Michael CoughlinSan Francisco$1.6M
- Charles ParksSan Francisco$225K
- John SchuberthSan Francisco$216K
- Colin TraynorSan Francisco$75K
- Eric GizaSacramento$3.6M
- Thomas HarrisPasadena$3M
- Thomas ChangSanta Rosa$2M
- Vladimir ZeetserEncino$677K
- Jason NowakRedding$526K
- Candice BradyCamarillo$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.